MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 14, 2006; DOI: 10.1124/mol.106.022772


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.022772v1
69/6/1849    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanders, J. M
Right arrow Articles by Swanson, G. T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanders, J. M
Right arrow Articles by Swanson, G. T


Received for publication January 30, 2006.
Revised March 3, 2006.
Accepted for publication March 14, 2006.

Determination of binding site residues responsible for the subunit selectivity of novel marine-derived compounds on kainate receptors

James M Sanders 1, Olli T Pentikainen 2, Luca Settimo 3, Ulla Pentikainen 4, Muneo Shoji 5, Makoto Sasaki 5, Ryuichi Sakai 6, Mark S Johnson 3, Geoffrey T Swanson 1*

1 University of Texas Medical Branch 2 Abo Akademi University; University of Bristol 3 Abo Akademi University 4 University of Bristol 5 Tohoku University 6 Kitasato University

* Address correspondence to: E-mail: g.swanson{at}utmb.edu

Abstract

Dysiherbaine (DH) and related molecules are high-affinity, subunit-selective kainate receptor (KAR) ligands originally isolated from a marine sponge. To elucidate why two compounds, DH and MSVIII-19, bind selectively to the GluR5 but not to the KA2 KAR subunit, we used molecular dynamics simulations to generate binding models that were tested experimentally in radioligand binding and electrophysiological assays. Three candidate sites, Val685, Leu735, and Ser741 in GluR5, corresponding to Ile669, Phe719, and Met725 in KA2, were predicted to underlie the distinct binding profiles of the marine toxins. Single or multiple reciprocal mutations introduced into the receptor subunits produced a variety of effects on binding affinity. Most notably, mutation of Met725 to serine in KA2 increased the affinity of DH by 350-fold; in contrast, mutation of one or more of the residues in GluR5 did not markedly alter DH binding. MSVIII-19 affinity for the KA2 subunit was significantly increased in multiple site mutants, and reciprocal mutations in the GluR5 subunit produced substantial (700-fold) reductions in MSVIII-19 affinity. Physiological characterization of the double and triple mutant subunits demonstrated altered functional behavior consistent with the changes in binding affinity. The results provide experimental support for the importance of these three LBD residues and suggest steric hindrance in the KA2 subunit LBD is largely responsible for the very low affinity for the two compounds. In this study we identified the molecular basis for subunit selectivity of these marine-derived molecules on KARs, which could facilitate the rationale design of selective ligands with distinct pharmacological profiles.


Key words: Glutamate, Molecular dynamics, Func. analysis receptor/ion channel mutants, Mutagenesis/Chimeric approaches, Receptor binding studies


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
Y. Zhang, N. Nayeem, and T. Green
Mutations to the Kainate Receptor Subunit GluR6 Binding Pocket That Selectively Affect Domoate Binding
Mol. Pharmacol., October 1, 2008; 74(4): 1163 - 1169.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. L. Lash, J. M. Sanders, N. Akiyama, M. Shoji, P. Postila, O. T. Pentikainen, M. Sasaki, R. Sakai, and G. T. Swanson
Novel Analogs and Stereoisomers of the Marine Toxin Neodysiherbaine with Specificity for Kainate Receptors
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 484 - 496.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics